Table of Contents

• What is Nofazinlimab?
• Target Condition: Advanced Hepatocellular Carcinoma
• Study Design
• Treatment Approach
• Expected Outcomes
• Safety Considerations
• Quality of Life Assessment

What is Nofazinlimab?

Nofazinlimab, also known by its code name CS1003, is an investigational drug being studied for the treatment of advanced hepatocellular carcinoma (HCC). This is a type of liver cancer that has progressed to an advanced stage and cannot be treated with localized therapies^[1]. The drug is being tested in combination with another medication called lenvatinib, which is already used as a basic treatment for HCC.

Target Condition: Advanced Hepatocellular Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer. It typically occurs in people with chronic liver diseases, such as cirrhosis. When HCC is described as “advanced,” it means that the cancer has spread within the liver or to other parts of the body, making it difficult to treat with surgery or local therapies^[1].

Study Design

The study of Nofazinlimab is being conducted as a Phase III clinical trial. This means it’s in an advanced stage of testing, where researchers are trying to confirm if the new treatment is better than existing options. The study has the following key features^[1]:

• Multi-center: The study is being conducted at multiple hospitals or research centers.
• Double-blind: Neither the patients nor the doctors directly involved in their care know who is receiving Nofazinlimab and who is receiving a placebo.
• Randomized: Patients are randomly assigned to either receive Nofazinlimab or a placebo, along with lenvatinib.

Treatment Approach

The study is comparing two treatment approaches^[1]:

1. Nofazinlimab (CS1003) + Lenvatinib: Patients in this group receive Nofazinlimab through intravenous (IV) administration every 21 days, along with daily oral doses of lenvatinib.
2. Placebo + Lenvatinib: Patients in this group receive a placebo (a substance with no active drug) through IV every 21 days, along with daily oral doses of lenvatinib.

This approach allows researchers to determine if adding Nofazinlimab to the standard lenvatinib treatment provides additional benefits for patients with advanced HCC.

Expected Outcomes

The study aims to measure several important outcomes to determine the effectiveness of Nofazinlimab^[1]:

• Overall survival (OS): This is the main goal of the study, measuring how long patients live after starting the treatment.
• Objective response rate (ORR): This measures the percentage of patients whose tumors shrink or disappear after treatment.
• Progression-free survival (PFS): This measures how long patients live without their cancer getting worse.
• Duration of response (DoR): For patients whose tumors respond to treatment, this measures how long the response lasts.
• Disease control rate (DCR): This measures the percentage of patients whose disease is controlled (either shrinks or stays stable) with the treatment.

These outcomes will be assessed by both the study investigators and an independent review committee to ensure accuracy and objectivity.

Safety Considerations

As with any new treatment, monitoring the safety of Nofazinlimab is a crucial part of the study. The researchers will be closely tracking^[1]:

• The percentage of participants who experience adverse events (side effects)
• The levels of Nofazinlimab in patients’ blood
• The number of patients who develop antibodies against Nofazinlimab, which could potentially reduce its effectiveness

Quality of Life Assessment

In addition to measuring the medical outcomes, the study also aims to understand how the treatment affects patients’ quality of life. This will be assessed using a standardized questionnaire called the European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30). The researchers will measure the time it takes for patients to experience a significant worsening in their quality of life after starting the treatment^[1].